Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
RegulatoryapprovedZENBEXUSPositive
AI Analysis
Summary
Bristol Myers Squibb's ZENBEXUS (iberdomide) received FDA accelerated approval as the first approved CELMoD therapy for multiple myeloma, with efficacy measured using Hematogenix's proprietary MM MRD assay as the primary endpoint.
Outcome Details
FDA accelerated approval of ZENBEXUS (iberdomide) as the first approved CELMoD therapy for multiple myeloma
Importance:8/10
Sentiment:
0.90
FDA approvalaccelerated approvalmultiple myelomaCELMoDoncologydiagnostic assayprimary endpoint
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 19, 2026 12:32 PM